Delving into the Latest Updates on Aspirin/Atenolol/Hydrochlorothiazide/Ramipril/Simvastatin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

PolyPill, Polycap, Polypill

+ [1]

Target

ACE x COX x HMG-CoA reductase x NCC x β1-adrenergic receptor

Mechanism

ACE inhibitors(Angiotensin-converting enzyme inhibitors), COX inhibitors(Cyclooxygenases inhibitors), HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors)

+ [2]

Therapeutic Areas

Nervous System DiseasesCardiovascular Diseases

Active Indication

Cardiovascular DiseasesStrokeCoronary Disease+ [2]

Inactive Indication-

Originator Organization

Cadila Pharmaceuticals Ltd.

Active Organization

Zydus Lifesciences Ltd.

Cadila Pharmaceuticals Ltd.

Inactive Organization

Tehran University of Medical Sciences

Drug Highest PhaseApproved

First Approval Date

IN (14 Jul 2009),

Coronary Disease

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC25H38O5

InChIKeyRYMZZMVNJRMUDD-HGQWONQESA-N

CAS Registry79902-63-9

View All Structures (5)

The overall objective of the Stroke Minimization through Additive Anti-atherosclerotic Agents in Routine Treatment II (SMAART-II) is to deploy a hybrid study design to firstly, demonstrate the efficacy of a polypill (Polycap ®) containing fixed doses of antihypertensives, a statin, and antiplatelet therapy taken as two capsules, once daily orally in reducing composite vascular risk over 24 months vs. usual care among 500 recent stroke patients encountered at 12 hospitals in Ghana. Secondly, SMAART II seeks to develop an implementation strategy for routine integration and policy adoption of this polypill for post-stroke cardiovascular risk reduction in an under-resourced system burdened by suboptimal care and outcomes.

Start Date01 Mar 2025

Sponsor / Collaborator

Northern California Institute for Research & Education

NCT04633005

/ RecruitingEarly Phase 1IIT

Polypill Strategy for the Evidence-Based Management of Heart Failure With Reduced Ejection Fraction in an Underserved Patient Population

Heart failure with a reduced ejection fraction (HFrEF) represents a significant public health burden in the United States, with a growing prevalence particularly among African Americans and Hispanic Americans and individuals of low socioeconomic status (SES). Although effective therapies exist, gaps in their uptake contribute substantially to the excess burden of heart failure. The "polypill" is an inexpensive once daily pill containing three agents proven to improve morbidity and mortality in heart failure and represents potential strategy for increasing the utilization of proven HF therapies. The proposed study is a pragmatic, single-center, randomized trial to test the feasibility and effectiveness of a polypill-based strategy for the treatment of HFrEF in a low-income, racially diverse population.

Start Date15 Nov 2021

Sponsor / Collaborator

The University of Texas Southwestern Medical Center

NCT03541109

/ Unknown statusPhase 3IIT

Fixed Combination Therapy for Secondary Prevention of Major Cardiovascular Events

Cardiovascular diseases (CVD) are the leading cause of mortality and morbidity worldwide. The most important aspect of CVD secondary prevention is adherence to guideline-indicated pharmacological therapy which globally remains low. In previous studies, a Polypill containing fixed dose combination of essential drugs have improved patient adherence to these drugs. The effect of such a strategy on pharmacological therapy uptake, cost-effectiveness, and CVD recurrence in our setting will be assessed in this study. Participants hospitalized in three referral hospitals in Isfahan, Iran because of an acute myocardial infarction (MI) (ST elevation MI (STEMI) or non-ST elevation MI (NSTEMI)) will be randomized to either receiving Polypill or usual care after MI. Patient recruitment will be carried out at the time of patient discharge from the hospitals.

Start Date20 May 2019

Sponsor / Collaborator

Isfahan University of Medical Sciences

[+1]

100 Clinical Results associated with Aspirin/Atenolol/Hydrochlorothiazide/Ramipril/Simvastatin

Login to view more data

100 Translational Medicine associated with Aspirin/Atenolol/Hydrochlorothiazide/Ramipril/Simvastatin

Login to view more data

100 Patents (Medical) associated with Aspirin/Atenolol/Hydrochlorothiazide/Ramipril/Simvastatin

Login to view more data

12

Literatures (Medical) associated with Aspirin/Atenolol/Hydrochlorothiazide/Ramipril/Simvastatin

01 Nov 2022·International Immunopharmacology

Protective and vaccine dose-sparing efficacy of Poly I:C-functionalized calcium phosphate nanoparticle adjuvants in inactivated influenza vaccination

Article

Author: Lee, Jueun ; Ahn, So Yeon ; Le, Chau Thuy Tien ; Jung, Jaehan ; Ko, Eun-Ju ; Lee, Dong-Ha

Adjuvants are required to increase the immunogenicity and efficacy of vaccination and enable vaccine dose sparing. Polyinosinic-polycytidylic acid (Poly I:C), a toll-like receptor 3 agonist, is a promising adjuvant candidate that can induce cell-mediated immune responses; however, it remains unlicensed owing to its low stability and toxicity. Calcium phosphate (CaP), a biocompatible and biodegradable nanoparticle, is widely used in biomedicine for stable and targeted drug delivery. In this study, we developed Poly I:C-functionalized CaP (Poly-CaP) and evaluated its vaccine adjuvant efficacy in vitro and in vivo. A half dose of Poly-CaP nanoparticles showed similar efficacy to a full dose of soluble Poly I:C in stimulating bone marrow-derived dendritic cells and macrophages to secrete proinflammatory cytokines and express their activation markers. Immunization with a half dose of inactivated influenza vaccine in the presence of Poly I:C or Poly-CaP adjuvants induced sufficient antigen-specific humoral responses after boost immunization. Immunization with Poly I:C, CaP, or Poly-CaP-adjuvanted with a half dose of influenza vaccine showed comparable protective efficacy against lethal virus infection, with lower weight loss and virus titer than a full dose of influenza vaccine. The Poly-CaP adjuvant was effective in stimulating antigen-specific CD4+ T cell proliferation in the lungs. Collectively, our results showed that the Poly-CaP adjuvant enhanced antigen-specific cell-mediated immunity and humoral immune responses with vaccine dose-sparing effects, suggesting its potential as a novel vaccine adjuvant candidate.

01 Dec 2018·TrialsQ4 · MEDICINE

Stroke Minimization through Additive Anti-atherosclerotic Agents in Routine Treatment (SMAART): study protocol for a randomized controlled trial

Q4 · MEDICINE

ArticleOA

Author: Adamu, Sheila ; Sarfo-Kantanka, Osei ; Ovbiagele, Bruce ; Voeks, Jennifer ; Sethi, Vipin ; Obese, Vida ; Tagge, Raelle ; Sarfo, Fred Stephen

BACKGROUNDThere is an unprecedented rise in the prevalence of stroke in sub-Saharan Africa (SSA). Secondary prevention guidelines recommend that antihypertensive, statin and antiplatelet therapy be initiated promptly after ischemic stroke and adhered to in a persistent fashion to achieve optimal vascular-risk reduction. However, these goals are seldom realized in routine clinical care settings in SSA due to logistical challenges. We seek to assess whether a polypill containing fixed doses of three antihypertensive agents, a statin and antiplatelet therapy taken once daily per os for 12 months among recent stroke survivors would result in carotid intimal thickness regression compared with usual care (UC).METHODSThe Stroke Minimization through Additive Anti-atherosclerotic Agents in Routine Treatment (SMAART) trial is a phase 2, open-label, evaluator-blinded trial involving 120 Ghanaian recent-ischemic-stroke survivors. Using a computer-generated sequence, patients will be randomly allocated 1:1 into either the intervention arm or UC. Patients in the intervention arm will receive Polycap DS® (containing aspirin, 100 mg; atenolol, 50 mg; ramipril, 5 mg; thiazide, 12.5 mg; simvastatin, 20 mg) taken as two capsules once daily. Patients in the UC will receive separate, individual secondary preventive medications prescribed at the physician's discretion. Both groups will be followed for 12 months to assess changes in carotid intimal thickness regression - a surrogate marker of atherosclerosis - as primary outcome measure. Secondary outcome measures include adherence to therapy, safety and tolerability, health-related quality of life, patient satisfaction, functional status, depression and cognitive dysfunction.DISCUSSIONAn efficacy-suggesting SMAART trial could inform the future design of a multi-center, double-blinded, placebo-controlled, parallel-group, randomized controlled trial comparing the clinical efficacy of the polypill strategy for vascular risk moderation among stroke survivors in SSA.TRIAL REGISTRATIONClinicalTrials.gov , ID: NCT03329599 . Registered on 11 February 2017.

01 Dec 2018·American Heart JournalQ2 · MEDICINE

The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct

Q2 · MEDICINE

Article

Author: Paul Camacho Lopez ; Jessica Tyrwhitt ; Khalid Yusoff ; Peggy Gao ; Habib Gamra ; Jackie Bosch ; Philip Joseph ; Prem Pais ; Antonio L Dans ; Karen Yeates ; Patricio Lopez-Jaramillo ; Salim Yusuf ; Anwar Santoso ; Denis Xavier ; Shamim Talukder ; Koon Teo

BACKGROUNDIt is hypothesized that in individuals without clinical cardiovascular disease (CVD), but at increased CVD risk, a 50% to 60% reduction in CVD risk could be achieved using fixed dose combination (FDC) therapy (usually comprised of multiple blood-pressure agents and a statin [with or without aspirin]) in a single "polypill". However, the impact of a polypill in preventing clinical CV events has not been evaluated in a large randomized controlled trial.METHODSTIPS-3 is a 2x2x2 factorial randomized controlled trial that will examine the effect of a FDC polypill on major CV outcomes in a primary prevention population. This study aims to determine whether the Polycap (comprised of atenolol, ramipril, hydrochlorothiazide, and a statin) reduces CV events in persons without a history of CVD, but who are at least at intermediate CVD risk. Additional interventions in the factorial design of the study will compare the effect of (1) aspirin versus placebo on CV events (and cancer), (2) vitamin D versus placebo on the risk of fractures, and (3) the combined effect of aspirin and the Polycap on CV events.RESULTSThe study has randomized 5713 participants across 9 countries. Mean age of the study population is 63.9 years, and 53% are female. Mean INTERHEART risk score is 16.8, which is consistent with a study population at intermediate CVD risk.CONCLUSIONResults of the TIP-3 study will be key to determining the appropriateness of FDC therapy as a strategy in the global prevention of CVD.

100 Deals associated with Aspirin/Atenolol/Hydrochlorothiazide/Ramipril/Simvastatin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	C03AX01	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Cardiovascular Diseases	IN	Cadila Pharmaceuticals Ltd.	30 Jan 2014
Stroke	IN	Cadila Pharmaceuticals Ltd.	17 Jul 2009
Coronary Disease	IN	Cadila Pharmaceuticals Ltd.	14 Jul 2009
Coronary Artery Disease	-	Zydus Lifesciences Ltd.	-
Hypertension	-	Zydus Lifesciences Ltd.	-

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cardiovascular Diseases	Discovery	IR	Tehran University of Medical Sciences	01 Oct 2011

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01404078 (TIPSK, CTgov)	Not Applicable	Peripheral Vascular Diseases \| Diabetes Mellitus, Type 2 \| Ischemic stroke \| Myocardial Ischemia	518	statin+Polycap+aspirin (Two Doses of Low Strength Polycap)	yhaggrefuv(kudejuexvc) = dbzfxcpmzo yzetytcpcf (kxhqtryqfx, nzmlppbqao - kvvdslewxr) View more	-	01 Dec 2014
NCT01404078 (TIPSK, CTgov)	Not Applicable		518	Srength Polycap (One Dose of Low Srength Polycap)	yhaggrefuv(kudejuexvc) = fqbshhhtum yzetytcpcf (kxhqtryqfx, jtpjdjvwiv - czkqpdhzdb) View more	-	01 Dec 2014
NCT00443794 (TIPS, Pubmed \| Lancet)	Phase 2	Cardiovascular Diseases	2,053	Polycap	(ogficbpcdz) = opprcvbtvh oorfahzspy (ncasuhluuq, 0.62 - 0.78)	-	18 Apr 2009